MEDITE Cancer Diagnostics, Inc. Announces Change of Auditor
PR Newswire - Thu May 14, 6:07PM CDT
MEDITE Cancer Diagnostics, Inc., ("Company," OTCQB symbol: "MDIT"
MEDITE Cancer Diagnostics, Inc. Announces short Delay for 10k Filing of 2014 Financials
PR Newswire - Thu Apr 16, 6:00AM CDT
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases announces a delay in the filing of the Form - 10k with the Securities and Exchange Commission.
MEDITE Cancer Diagnostics, Inc. Announces Granted Patent "Lab-in-One Automation" System
PR Newswire - Fri Mar 20, 11:59AM CDT
MEDITE Cancer Diagnostics, Inc., (MDIT) specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and related diseases announced the recent decision of the German Patent Register to grant MEDITE the German priority patent for its Histology "Lab-in-one Automation" System. Based on this success MEDITE will finish its nationalization applications for USA, China and UK before April 4th, 2015.